Risk factors for carotid plaque progression after optimising the risk factor treatment: substudy results of the Atherosclerotic Plaque Characteristics Associated with a Progression Rate of the Plaque and a Risk of Stroke in Patients with the carotid Bifurcation Plaque Study (ANTIQUE).
atherosclerosis
plaque
stenosis
ultrasonography
Journal
Stroke and vascular neurology
ISSN: 2059-8696
Titre abrégé: Stroke Vasc Neurol
Pays: England
ID NLM: 101689996
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
19
04
2021
accepted:
07
10
2021
pubmed:
3
12
2021
medline:
30
4
2022
entrez:
2
12
2021
Statut:
ppublish
Résumé
Carotid plaque progression contributes to increasing stroke risk. The study aims to identify factors influencing carotid plaque thickness progression after changing the preventive treatment to the 'treating arteries instead of risk factors' strategy, that is, change in treatment depending on the progression of atherosclerosis. The study participants who completed sonographic controls over the course of 3 years were enrolled to the analysis. Duplex sonography of cervical arteries was performed in 6-month intervals with measurement of carotid plaque thickness. Plaque thickness measurement error (σ) was set as 3 SD. Only evidently stable and progressive plaques (defined as plaque thickness difference between initial and final measurements of ˂σ and >2σ, respectively) were included to analysis. Univariate and multivariate logistic regression analysis was performed to identify factors influencing plaque progression. A total of 1391 patients (466 males, age 67.2±9.2 years) were enrolled in the study. Progressive plaque in at least one carotid artery was detected in 255 (18.3%) patients. Older age, male sex, greater plaque thickness, coronary heart disease, vascular surgery/stenting history and smoking were more frequently present in patients with progressive plaque (p˂0.05 in all cases). Multivariate logistic regression analysis identified only the plaque thickness (OR 1.850 for left side, 95% CI 1.398 to 2.449; and OR 1.376 for right side, 95% CI 1.070 to 1.770) as an independent factor influencing plaque progression. Carotid plaque thickness corresponding to stenosis severity is the only independent risk factor for plaque thickness progression after optimising the prevention treatment. NCT02360137.
Sections du résumé
BACKGROUND AND AIM
Carotid plaque progression contributes to increasing stroke risk. The study aims to identify factors influencing carotid plaque thickness progression after changing the preventive treatment to the 'treating arteries instead of risk factors' strategy, that is, change in treatment depending on the progression of atherosclerosis.
METHODS
The study participants who completed sonographic controls over the course of 3 years were enrolled to the analysis. Duplex sonography of cervical arteries was performed in 6-month intervals with measurement of carotid plaque thickness. Plaque thickness measurement error (σ) was set as 3 SD. Only evidently stable and progressive plaques (defined as plaque thickness difference between initial and final measurements of ˂σ and >2σ, respectively) were included to analysis. Univariate and multivariate logistic regression analysis was performed to identify factors influencing plaque progression.
RESULTS
A total of 1391 patients (466 males, age 67.2±9.2 years) were enrolled in the study. Progressive plaque in at least one carotid artery was detected in 255 (18.3%) patients. Older age, male sex, greater plaque thickness, coronary heart disease, vascular surgery/stenting history and smoking were more frequently present in patients with progressive plaque (p˂0.05 in all cases). Multivariate logistic regression analysis identified only the plaque thickness (OR 1.850 for left side, 95% CI 1.398 to 2.449; and OR 1.376 for right side, 95% CI 1.070 to 1.770) as an independent factor influencing plaque progression.
CONCLUSION
Carotid plaque thickness corresponding to stenosis severity is the only independent risk factor for plaque thickness progression after optimising the prevention treatment.
TRIAL REGISTRATION NUMBER
NCT02360137.
Identifiants
pubmed: 34853082
pii: svn-2021-001068
doi: 10.1136/svn-2021-001068
pmc: PMC9067273
doi:
Banques de données
ClinicalTrials.gov
['NCT02360137']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
132-139Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur Heart J. 2012 Jul;33(13):1635-701
pubmed: 22555213
Cardiovasc Diagn Ther. 2020 Aug;10(4):1048-1067
pubmed: 32968660
Stroke. 2002 Dec;33(12):2916-22
pubmed: 12468791
Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2860-2869
pubmed: 34353703
BMJ. 2011 Mar 11;342:d556
pubmed: 21398359
Stroke. 2017 Jun;48(6):1624-1629
pubmed: 28487327
Neurology. 2008 Apr 1;70(14):1200-7
pubmed: 18354078
J Am Soc Echocardiogr. 2008 Oct;21(10):1156-62
pubmed: 18558473
Sci Rep. 2016 May 12;6:25733
pubmed: 27169625
Ann Transl Med. 2020 Oct;8(19):1262
pubmed: 33178794
Cardiol Clin. 2015 Feb;33(1):1-35
pubmed: 25439328
Eur Heart J Cardiovasc Imaging. 2018 Sep 1;19(9):1042-1050
pubmed: 29059296
J Hypertens. 2013 Oct;31(10):1925-38
pubmed: 24107724
Lancet. 2019 Jan 12;393(10167):133-142
pubmed: 30522919
Stroke. 2012 Jun;43(6):1596-601
pubmed: 22511010
Lancet. 1998 May 9;351(9113):1379-87
pubmed: 9593407
Arch Neurol. 2010 Feb;67(2):180-6
pubmed: 20008646
World J Diabetes. 2016 Sep 15;7(17):396-405
pubmed: 27660696
AJNR Am J Neuroradiol. 2018 Feb;39(2):E9-E31
pubmed: 29326139
Stroke. 1979 May-Jun;10(3):238-45
pubmed: 462508
Stroke. 2010 Jun;41(6):1193-9
pubmed: 20413738
Circulation. 2006 May 16;113(19):2320-8
pubmed: 16651471
Stroke. 2012 Mar;43(3):916-21
pubmed: 22343647
Neuroepidemiology. 2013;40(1):36-41
pubmed: 23075828
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
BMC Public Health. 2015 Jul 24;15:701
pubmed: 26205716